Wolf Popper LLP Announces Investigation on Behalf of Investors in Obalon Therapeutics, Inc.

NEW YORK, Jan. 24, 2018 /PRNewswire/ -- Wolf Popper LLP is investigating potential securities fraud claims on behalf of investors in Obalon Therapeutics, Inc. (NASDAQ: OBLN).  Obalon investors should contact Fei-Lu Qian at 877.370.7703 or at fqian@wolfpopper.com.

On January 23, 2018, Obalon issued a press release disclosing the termination of its common stock public offering of $5.50 per share after a "whistleblower contacted KPMG LLP, the Company's independent auditors, to make certain allegations relating to allegedly improper revenue recognition during the Company's fourth fiscal quarter of 2017…."

As a result of the disclosure, Obalon stock price declined $1.73 per share or 33%, to close at $3.46 per share on January 23, 2018.

Wolf Popper has successfully recovered billions of dollars for defrauded investors.  The firm's reputation and expertise have been repeatedly recognized by the courts, which have appointed the firm to major positions in securities litigation.  See www.wolfpopper.com.

Attorney Advertising: Prior Results Do Not Guarantee A Similar Outcome.

Wolf Popper LLP
Fei-Lu Qian
845 Third Avenue
New York, NY 10022
Tel.: 877.370.7703
Fax: 877.370.7704
Email: fqian@wolfpopper.com

View original content:http://www.prnewswire.com/news-releases/wolf-popper-llp-announces-investigation-on-behalf-of-investors-in-obalon-therapeutics-inc-300587533.html

SOURCE Wolf Popper LLP